Literature DB >> 22371455

Mesothelin overexpression promotes mesothelioma cell invasion and MMP-9 secretion in an orthotopic mouse model and in epithelioid pleural mesothelioma patients.

Elliot L Servais1, Christos Colovos, Luis Rodriguez, Adam J Bograd, Jun-ichi Nitadori, Camelia Sima, Valerie W Rusch, Michel Sadelain, Prasad S Adusumilli.   

Abstract

PURPOSE: Mesothelin (MSLN) is a tumor-associated antigen, being investigated as a biomarker and therapeutic target in malignant pleural mesothelioma (MPM). The biologic function of MSLN overexpression in MPM is unknown. We hypothesized that MSLN may promote tumor invasion in MPM, a tumor characterized primarily by regional aggressiveness and rare distant metastases. EXPERIMENTAL
DESIGN: Human and murine MPM cells with MSLN forced expression and short hairpin RNA knockdown were examined for proliferation, invasion, and matrix metalloproteinase (MMP) secretion. The influence of MSLN overexpression on MPM cell invasion was assessed in an orthotopic mouse model and in patient samples.
RESULTS: MSLN expression promotes MPM cell invasion and MMP secretion in both human and murine MPM cells. In an orthotopic MPM mouse model characterized by our laboratory, MPM cells with MSLN overexpression preferentially localized to the tumor invading edge, colocalized with MMP-9 expression, and promoted decreased survival without an increase in tumor burden progression. In a tissue microarray from epithelioid MPM patients (n = 139, 729 cores), MSLN overexpression correlated with higher MMP-9 expression at individual core level. Among stage III MPM patients (n = 72), high MSLN expression was observed in 26% of T2 tumors and 51% of T3 tumors.
CONCLUSIONS: Our data provide evidence elucidating a biologic role for MSLN as a factor promoting tumor invasion and MMP-9 expression in MSLN expressing MPM. As regional invasion is the characteristic feature in MSLN expressing solid cancers (MPM, pancreas, and ovarian), our observations add rationale to studies investigating MSLN as a therapeutic target. ©2012 AACR.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22371455      PMCID: PMC3759995          DOI: 10.1158/1078-0432.CCR-11-2614

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  58 in total

1.  Anti-beta4 integrin antibodies enhance migratory and invasive abilities of human colon adenocarcinoma cells and their MMP-2 expression.

Authors:  N Daemi; N Thomasset; J C Lissitzky; J Dumortier; M F Jacquier; C Pourreyron; P Rousselle; J A Chayvialle; L Remy
Journal:  Int J Cancer       Date:  2000-03-15       Impact factor: 7.396

2.  Matrix metalloproteinases promote inflammation and fibrosis in asbestos-induced lung injury in mice.

Authors:  Roderick J Tan; Cheryl L Fattman; Laura M Niehouse; Jacob M Tobolewski; Lana E Hanford; Qinglang Li; Federico A Monzon; William C Parks; Tim D Oury
Journal:  Am J Respir Cell Mol Biol       Date:  2006-03-30       Impact factor: 6.914

3.  Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.

Authors:  Aravind Subramanian; Pablo Tamayo; Vamsi K Mootha; Sayan Mukherjee; Benjamin L Ebert; Michael A Gillette; Amanda Paulovich; Scott L Pomeroy; Todd R Golub; Eric S Lander; Jill P Mesirov
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-30       Impact factor: 11.205

4.  Pre-clinical mouse models of primary and metastatic pleural cancers of the lung and breast and the use of bioluminescent imaging to monitor pleural tumor burden.

Authors:  Elliot L Servais; Christos Colovos; Stefan S Kachala; Prasad S Adusumilli
Journal:  Curr Protoc Pharmacol       Date:  2011-09

5.  Minimally invasive localization of oncolytic herpes simplex viral therapy of metastatic pleural cancer.

Authors:  B M Stiles; P S Adusumilli; A Bhargava; S F Stanziale; T H Kim; M-K Chan; R Huq; R Wong; V W Rusch; Y Fong
Journal:  Cancer Gene Ther       Date:  2006-01-01       Impact factor: 5.987

6.  Determinants of incident vertebral fracture in men and women: results from the European Prospective Osteoporosis Study (EPOS).

Authors:  D K Roy; T W O'Neill; J D Finn; M Lunt; A J Silman; D Felsenberg; G Armbrecht; D Banzer; L I Benevolenskaya; A Bhalla; J Bruges Armas; J B Cannata; C Cooper; J Dequeker; M N Diaz; R Eastell; O B Yershova; B Felsch; W Gowin; S Havelka; K Hoszowski; A A Ismail; I Jajic; I Janott; O Johnell; J A Kanis; G Kragl; A Lopez Vaz; R Lorenc; G Lyritis; P Masaryk; C Matthis; T Miazgowski; C Gennari; H A P Pols; G Poor; H H Raspe; D M Reid; W Reisinger; C Scheidt-Nave; J J Stepan; C J Todd; K Weber; A D Woolf; J Reeve
Journal:  Osteoporos Int       Date:  2003-01       Impact factor: 4.507

7.  Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions.

Authors:  Harvey I Pass; Anil Wali; Naimei Tang; Alla Ivanova; Sergey Ivanov; Michael Harbut; Michele Carbone; Jeffrey Allard
Journal:  Ann Thorac Surg       Date:  2008-01       Impact factor: 4.330

8.  Prognostic significance of MMP-9 and TIMP-1 serum and tissue expression in breast cancer.

Authors:  Zheng-Sheng Wu; Qiang Wu; Jiu-Hua Yang; Hong-Qun Wang; Xiang-Dong Ding; Feng Yang; Xiao-Chun Xu
Journal:  Int J Cancer       Date:  2008-05-01       Impact factor: 7.396

9.  Quantitative monitoring of adenocarcinoma development in rodents by magnetic resonance imaging.

Authors:  Joel R Garbow; Min Wang; Yian Wang; Ronald A Lubet; Ming You
Journal:  Clin Cancer Res       Date:  2008-03-01       Impact factor: 12.531

10.  Soluble mesothelin-related Peptide and osteopontin as markers of response in malignant mesothelioma.

Authors:  Paul Wheatley-Price; Boming Yang; Demetris Patsios; Devalben Patel; Clement Ma; Wei Xu; Natasha Leighl; Ronald Feld; B C John Cho; Brenda O'Sullivan; Heidi Roberts; Ming Sound Tsao; Martin Tammemagi; Masaki Anraku; Zhuo Chen; Marc de Perrot; Geoffrey Liu
Journal:  J Clin Oncol       Date:  2010-05-24       Impact factor: 44.544

View more
  77 in total

Review 1.  Immunotherapy for non-small cell lung cancer: current concepts and clinical trials.

Authors:  Marissa Mayor; Neng Yang; Daniel Sterman; David R Jones; Prasad S Adusumilli
Journal:  Eur J Cardiothorac Surg       Date:  2015-10-29       Impact factor: 4.191

Review 2.  Malignant pleural mesothelioma: an update on diagnosis and treatment options.

Authors:  Sanjana Kondola; David Manners; Anna K Nowak
Journal:  Ther Adv Respir Dis       Date:  2016-02-12       Impact factor: 4.031

3.  Generation of a Transgenic BALB/c Mouse Line With Selective Expression of Human Mesothelin in Thyroid Gland: Application in Mesothelin-targeted Immunotherapy.

Authors:  Tapan K Bera; Wenlong Liu; Jasmin Leshem; Emily King; Serguei Kozlov; Ira Pastan
Journal:  J Immunother       Date:  2019-05       Impact factor: 4.456

Review 4.  Diagnostic and prognostic biomarkers for malignant mesothelioma: an update.

Authors:  Zhongjian Chen; Giovanni Gaudino; Harvey I Pass; Michele Carbone; Haining Yang
Journal:  Transl Lung Cancer Res       Date:  2017-06

Review 5.  Immunotherapy for malignant pleural mesothelioma: current status and future directions.

Authors:  Jordan Dozier; Hua Zheng; Prasad S Adusumilli
Journal:  Transl Lung Cancer Res       Date:  2017-06

6.  Mesothelin-targeted immunotherapies for malignant pleural mesothelioma.

Authors:  Jonathan Villena-Vargas; Prasad S Adusumilli
Journal:  Ann Cardiothorac Surg       Date:  2012-11

Review 7.  The Role of Mesothelin as a Diagnostic and Therapeutic Target in Pancreatic Ductal Adenocarcinoma: A Comprehensive Review.

Authors:  Federico Nichetti; Antonio Marra; Francesca Corti; Alessandro Guidi; Alessandra Raimondi; Natalie Prinzi; Filippo de Braud; Sara Pusceddu
Journal:  Target Oncol       Date:  2018-06       Impact factor: 4.493

Review 8.  Re-adapting T cells for cancer therapy: from mouse models to clinical trials.

Authors:  Ingunn M Stromnes; Thomas M Schmitt; Aude G Chapuis; Sunil R Hingorani; Philip D Greenberg
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

9.  Expression of matrix metalloproteinase-2 and 9 in cervical intraepithelial neoplasia and cervical carcinoma among different age groups of premenopausal and postmenopausal women.

Authors:  Arnab Ghosh; Anuradha Moirangthem; Rabindranath Dalui; TapanKumar Ghosh; Arghya Bandyopadhyay; Anindya Dasgupta; Uma Banerjee; Narayan Jana; Anupam Basu
Journal:  J Cancer Res Clin Oncol       Date:  2014-05-08       Impact factor: 4.553

Review 10.  Clinical impacts of mesothelin expression in gastrointestinal carcinomas.

Authors:  Takahiro Einama; Futoshi Kawamata; Hirofumi Kamachi; Hiroshi Nishihara; Shigenori Homma; Fumihiko Matsuzawa; Tatsuzo Mizukami; Yuji Konishi; Munenori Tahara; Toshiya Kamiyama; Okio Hino; Akinobu Taketomi; Satoru Todo
Journal:  World J Gastrointest Pathophysiol       Date:  2016-05-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.